Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 11/20 | 0.64 |
| ▸ | PRSS2 | P07478 | 11/20 | 0.64 |
| ▸ | PRSS3 | P35030 | 11/20 | 0.64 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13834778 | 0.87 | AVPR1A (0.57) | PRSS1PRSS2PRSS3AVPR1AMAOA | |
| SCHEMBL2109527 | 0.87 | PRSS1 (0.57) | PRSS1PRSS2PRSS3AVPR1AMAOA | |
| SCHEMBL2109873 | 0.86 | PRSS1 (0.58) | PRSS1PRSS2PRSS3MAOAMAOB | |
| SCHEMBL4356598 | 0.85 | AVPR1A (0.78) | AVPR1A | |
| SCHEMBL19387565 | 0.82 | AVPR1A (0.52) | PRSS1PRSS2PRSS3AVPR1AMAOA | |
| SCHEMBL2109366 | 0.81 | PRSS1 (0.74) | PRSS1PRSS2PRSS3MAOAMAOB | |
| SCHEMBL2107810 | 0.81 | PRSS1 (0.61) | PRSS1PRSS2PRSS3MAOAMAOB | |
| SCHEMBL13835998 | 0.80 | PRSS1 (0.56) | PRSS1PRSS2PRSS3AVPR1AMAOA | |
| SCHEMBL2109534 | 0.80 | PRSS1 (0.62) | PRSS1PRSS2PRSS3MAOAMAOB | |
| SCHEMBL2109196 | 0.79 | PRSS1 (0.61) | PRSS1PRSS2PRSS3MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | COSTANZO MICHAEL J (US) | 2012-06-28 | — | — | US | claimed |
| US-8158792-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | claimed |
| EP-2224803-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2010-09-08 | — | — | EP | claimed |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2009-06-25 | — | — | US | claimed |
| WO-2009067202-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-28 | — | — | WO | claimed |
| EP-2224803-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009067202-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | PRSS1 7/4885PRSS2 33/4885PRSS3 9/4885 |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | TPSAB1, TPSB2, TPSD1 | PRSS1 7/4885PRSS2 33/4885PRSS3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.